Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Terns Pharmaceuticals (TERN) EBIAT (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of EBIAT readings, the most recent being -$23.6 million for Q4 2025.

  • Quarterly EBIAT fell 8.13% to -$23.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$96.2 million through Dec 2025, down 8.28% year-over-year, with the annual reading at -$96.2 million for FY2025, 8.28% down from the prior year.
  • EBIAT hit -$23.6 million in Q4 2025 for Terns Pharmaceuticals, up from -$24.6 million in the prior quarter.
  • Across five years, EBIAT topped out at -$10.7 million in Q2 2021 and bottomed at -$29.8 million in Q3 2023.
  • Average EBIAT over 5 years is -$19.3 million, with a median of -$21.3 million recorded in 2023.
  • The largest annual shift saw EBIAT tumbled 76.97% in 2023 before it rose 26.28% in 2024.
  • Terns Pharmaceuticals' EBIAT stood at -$14.2 million in 2021, then dropped by 11.05% to -$15.8 million in 2022, then crashed by 32.85% to -$21.0 million in 2023, then decreased by 3.71% to -$21.8 million in 2024, then dropped by 8.13% to -$23.6 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's EBIAT are -$23.6 million (Q4 2025), -$24.6 million (Q3 2025), and -$24.1 million (Q2 2025).